Prevalence of Diabetes Mellitus and Metabolic Syndrome in Prostate Cancer Patients given Androgen Deprivation Therapy

Rivera-Arkoncel, Maria Luisa Cecilia; Sagun, Michael; Arkoncel, Francis Raymond P.; Jimeno, Cecilia; Lapitan, Marie Carmela

doi:10.15605/jafes.029.01.06

Cited by 2 publications

(1 citation statement)

References 40 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A new onset fasting hyperglycaemic episode was noted in four (4.10%) patients in the MC group. Studies have confirmed the link of ADT and diabetes mellitus [50][51][52][53][54][55]. There is a decrease in number of skeletal muscles fibres during ADT therapy leading to reduction in peripheral glucose uptake by muscle tissues.…”

Section: Discussionmentioning

confidence: 83%

Orchiectomy Versus Goserelin Each Plus Bicalutamide in Patients with Metastatic Adenocarcinoma of the Prostate: Adverse Events Highlighted

Odoemene

2019

JUNS

View full text Add to dashboard Cite

Background: Androgen deprivation therapy (ADT), palliation for advanced/metastatic prostate cancer can be medical or surgical. This study compares the results of goserelin injection to orchiectomy each in combination with bicalutamide in patients diagnosed with metastatic adenocarcinoma of the prostate highlighting the adverse events.Methods: Ninety-six patients with histologically diagnosed adenocarcinoma of the prostate, were prospectively randomized into two arms. Medical arm patients had subcutaneous goserelin injection plus bicalutamide. Surgical arm patients had bilateral orchiectomy plus bicalutamide. A nadir serum prostate specific antigen (PSA) of 0.2ng/ml was chosen and response to treatment was by determining total serum PSA levels at 3 and 6 months. The student's t test, chi-squared test and Kaplan-Meier survival analysis were the instruments for statistical analysis.Results: Follow up was between 6-30 months. There were 11 (23%) and 9 (19%) deaths in the surgical and medical arms respectively. At 6 months serum PSA levels of ≤ 0.2ng/ml was noted in 44 (92%) and 45 (94%) patients of the medical and surgical castrations respectively. Anemia, impotence, hot flushes were some of the adverse events noted in both groups during the study worse with medical castration. Conclusion:There was no statistical difference between the oncological efficacy and survival of both arms of treatment but a statistical difference in the adverse events

show abstract

Section: Discussionmentioning

confidence: 83%

Orchiectomy Versus Goserelin Each Plus Bicalutamide in Patients with Metastatic Adenocarcinoma of the Prostate: Adverse Events Highlighted

Odoemene

2019

JUNS

View full text Add to dashboard Cite

show abstract

Enzalutamide versus abiraterone acetate in the development of new-onset or worsening type 2 diabetes mellitus in patients with metastatic castration-resistant prostate cancer: EVADE study

Bahl,

Sodatonou,

Snjider

et al. 2024

World J Urol

View full text Add to dashboard Cite

Purpose To determine new-onset or worsening T2DM risk in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate (AA) vs. enzalutamide (ENZA) in England. Methods Records of patients on AA and/or ENZA (2015−2021) were analysed retrospectively from UK- or England-wide databases and data sets. The primary endpoint was new-onset or worsening T2DM, analysed using a Cox model. Results Of 1382 patients, 84 (6.1%) met the primary endpoint; 42 of 826 patients (5.1%) received ENZA and 42 of 556 patients (7.6%) received AA. Among patients without baseline T2DM ( n = 1049), 50 developed new-onset T2DM: 24 (3.9%) on ENZA and 26 (5.9%) on AA. Among patients with baseline T2DM ( n = 333), 34 (10.2%) had worsening T2DM: 18 (8.3%) on ENZA and 16 (13.8%) on AA. Patients on ENZA had longer median follow-up (445 vs. 408 days) and treatment duration (164 vs. 139 days) than those on AA, who were also more likely to have new-onset or worsening T2DM than those on ENZA (HR: 1.8; 95% CI: 1.4–2.7; P = 0.0101). The number needed to harm for an additional patient to experience new-onset or worsening T2DM when receiving AA instead of ENZA was 40 overall, 50 in patients without baseline T2DM, and 18 in patients with baseline T2DM. Conclusion Patients with mCRPC receiving AA were more likely to experience new-onset or worsening T2DM than those on ENZA, despite having a shorter treatment duration. Further research is required to substantiate these findings in earlier disease settings with longer treatment duration. Supplementary Information The online version contains supplementary material available at 10.1007/s00345-024-05280-y.

show abstract

Prevalence of Diabetes Mellitus and Metabolic Syndrome in Prostate Cancer Patients given Androgen Deprivation Therapy

Cited by 2 publications

References 40 publications

Orchiectomy Versus Goserelin Each Plus Bicalutamide in Patients with Metastatic Adenocarcinoma of the Prostate: Adverse Events Highlighted

Orchiectomy Versus Goserelin Each Plus Bicalutamide in Patients with Metastatic Adenocarcinoma of the Prostate: Adverse Events Highlighted

Enzalutamide versus abiraterone acetate in the development of new-onset or worsening type 2 diabetes mellitus in patients with metastatic castration-resistant prostate cancer: EVADE study

Contact Info

Product

Resources

About